Structure via PubChem · Public domain (PubChem)
deferasirox
Sign in to saveAlso known as ICL670, ICL670A, ICL 670a, ICL 670, deferasiroxum
Deferasirox, sold under the brand name Exjade among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 460774502
- Drug.image
- Deferasirox.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 180
- Drug.image2
- Deferasirox ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.pronounce
- de FER a sir ox
- Drug.tradename
- Exjade, others
- Drug.MedlinePlus
- a606002
- Drug.DailyMedID
- Deferasirox
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- V03
- Drug.ATC_suffix
- AC03
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C21H15N3O4
- Molecular weight
- 373.4 g/mol
- IUPAC name
- 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
- SMILES
- C1=C/C(=C/2\N/C(=C\3/C=CC=CC3=O)/N(N2)C4=CC=C(C=C4)C(=O)O)/C(=O)C=C1
- InChIKey
- FMSOAWSKCWYLBB-VBGLAJCLSA-N
- XLogP
- 3.8
- Polar surface area
- 98.7 Ų
- H-bond donors
- 3
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2005
- Admin. routes
- oral
- Indications
- Beta-thalassemia, anemia (phenotype), myelodysplastic syndrome, liver disease
via ChEMBL · EBI
Research
1,446 papers- Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota.Life sciences · 2023
- Deferasirox.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2007
- Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload.Vox sanguinis · 2021
- Deferasirox nephrotoxicity-the knowns and unknowns.Nature reviews. Nephrology · 2014
- Deferasirox: pharmacokinetics and clinical experience.Expert opinion on drug metabolism & toxicology · 2012
via PubMed
Wikidata facts
- Subclass of
- heterocyclic compound
- Mass
- 373.10625596
- Has use
- medication
Show 7 more facts
- chemical formula
- C₂₁H₁₅N₃O₄
- canonical SMILES
- OC(=O)c1ccc(cc1)n2nc(nc2c3ccccc3O)c4ccccc4O
- World Health Organisation international non-proprietary name
- deferasirox
- NCI Thesaurus ID
- C48384
- medical condition treated
- myelofibrosis
- Commons category
- Deferasirox
- legal status (medicine)
- boxed warning
Sources (6)
via Wikidata · CC0
~3 min read
Encyclopedic overview
4 sectionsContents
- Properties
- Synthesis
- Risks
- References
Deferasirox, sold under the brand name Exjade among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose.
It was approved by the US Food and Drug Administration (FDA) in November 2005. According to the FDA (May 2007), kidney failure and cytopenias have been reported in patients receiving deferasirox tablets for oral suspension. It is approved in the European Union by the European Medicines Agency (EMA) for children six years and older for chronic iron overload from repeated blood transfusions. It is on the World Health Organization's List of Essential Medicines.
Excerpted from Wikipedia’s “deferasirox” article, available under the CC BY-SA 4.0 licence.